JP2015531396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531396A5 JP2015531396A5 JP2015535741A JP2015535741A JP2015531396A5 JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibody
- subject
- mabp1
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (7)
- ヒト被験者の不安を軽減するための医薬品の製造における、医薬的に許容可能なキャリアと、前記被験者の不安を軽減するのに有効な量の、ＩＬ−１αと選択的に結合する剤とを含む医薬組成物の使用。
- 請求項１に記載の使用において、前記剤は、抗−ＩＬ−１α抗体であることを特徴とする使用。
- 請求項２に記載の使用において、前記抗−ＩＬ−１α抗体は、モノクローナル抗体であることを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体は、ＩｇＧ１であることを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体は、ＭＡＢｐ１の相補性決定領域を含むことを特徴とする使用。
- 請求項３に記載の使用において、前記モノクローナル抗体は、ＭＡＢｐ１であることを特徴とする使用。
- 請求項１に記載の使用において、前記被験者は、ざ瘡があることを特徴とする使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709741P | 2012-10-04 | 2012-10-04 | |
| US61/709,741 | 2012-10-04 | ||
| PCT/US2013/062899 WO2014055541A1 (en) | 2012-10-04 | 2013-10-01 | Treatment of psychiatric conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090717A Division JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531396A JP2015531396A (ja) | 2015-11-02 |
| JP2015531396A5 true JP2015531396A5 (ja) | 2016-11-17 |
| JP6750941B2 JP6750941B2 (ja) | 2020-09-02 |
Family
ID=50435375
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535741A Active JP6750941B2 (ja) | 2012-10-04 | 2013-10-01 | 精神障害の治療 |
| JP2020090717A Pending JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
| JP2022144756A Withdrawn JP2022177132A (ja) | 2012-10-04 | 2022-09-12 | 精神障害の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020090717A Pending JP2020143133A (ja) | 2012-10-04 | 2020-05-25 | 精神障害の治療 |
| JP2022144756A Withdrawn JP2022177132A (ja) | 2012-10-04 | 2022-09-12 | 精神障害の治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2903643A4 (ja) |
| JP (3) | JP6750941B2 (ja) |
| KR (1) | KR20150064091A (ja) |
| CN (1) | CN104684581A (ja) |
| AU (1) | AU2013327498B2 (ja) |
| CA (1) | CA2886757C (ja) |
| WO (1) | WO2014055541A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102167261B1 (ko) | 2010-06-18 | 2020-10-20 | 엑스바이오테크, 인크. | 관절염 치료 |
| KR102314003B1 (ko) | 2010-08-23 | 2021-10-19 | 얀센 바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| MX2019009798A (es) * | 2017-02-16 | 2020-01-30 | Xbiotech Inc | Tratamiento de la hidradenitis supurativa. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405021D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| US5455234A (en) * | 1994-03-16 | 1995-10-03 | Ahluwalia; Gurpreet S. | Inhibition of hair growth |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| CN103656638B (zh) * | 2008-05-30 | 2016-04-27 | 埃克斯生物科技公司 | 白细胞介素-1α抗体及使用方法 |
| TW201031421A (en) * | 2009-01-29 | 2010-09-01 | Abbott Lab | IL-1 binding proteins |
| JP6062918B2 (ja) * | 2011-04-01 | 2017-01-18 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 皮膚科的病理の治療 |
| US9724409B2 (en) * | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
-
2013
- 2013-10-01 JP JP2015535741A patent/JP6750941B2/ja active Active
- 2013-10-01 KR KR1020157009988A patent/KR20150064091A/ko not_active IP Right Cessation
- 2013-10-01 CA CA2886757A patent/CA2886757C/en active Active
- 2013-10-01 WO PCT/US2013/062899 patent/WO2014055541A1/en active Application Filing
- 2013-10-01 AU AU2013327498A patent/AU2013327498B2/en not_active Ceased
- 2013-10-01 EP EP13843079.8A patent/EP2903643A4/en not_active Withdrawn
- 2013-10-01 CN CN201380050428.0A patent/CN104684581A/zh active Pending
-
2020
- 2020-05-25 JP JP2020090717A patent/JP2020143133A/ja active Pending
-
2022
- 2022-09-12 JP JP2022144756A patent/JP2022177132A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531396A5 (ja) | ||
| JP2014509662A5 (ja) | ||
| IL240179A0 (en) | Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| PH12014501685A1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| IL240731B (en) | An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
| JP2014111603A5 (ja) | ||
| MX2019014658A (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina. | |
| WO2011088120A8 (en) | Antibody formulation and therapeutic regimens | |
| BR112013002167A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação | |
| JP2010222367A5 (ja) | ||
| HK1213782A1 (zh) | 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物 | |
| JP2012136529A5 (ja) | ||
| JP2015524816A5 (ja) | ||
| JP2014526559A5 (ja) | ||
| JP2015531397A5 (ja) | ||
| WO2014185908A3 (en) | Hybridoma clones, monoclonal antibodies, and methods of use | |
| DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| BR112013015509A2 (pt) | composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição | |
| BRPI0806529A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta |